A B S T R A C T An isotope dilution method, using 'Plabeled pyrophosphate, has been developed for the measurement of inorganic pyrophosphate (PP.) in human plasma. The specificity of the method was better than 90% as assessed by elution patterns during ion-exchange chromatography, by paper chromatography, and by incubation with inorganic pyrophosphatase. The 99% confidence limits for a single estimation of plasma PP. was -+-13%. There were no differences in plasma PPi between men and women, but the values in young people (0-15 yr) were slightly higher than in older people.
INTRODUCTION
Inorganic pyrophosphate (PP1) is known to be produced as a by-product of many biosynthetic reactions in
Introduction
The main difficulties in developing a satisfactory technique for measuring PP1 in plasma were that the concentrations of PP1 were very low, that other compounds appeared to interfere with the chemical determination, and that PP1 was subject to variable and often extensive hydrolysis during the analysis.
The method finally adopted was based on isotope dilution. In outline the essential steps were addition of 3P-labeled pyrophosphate to the blood at the time of collection, preparation of the plasma, deproteinization of the plasma by ultrafiltration, two coprecipitations of PP1 with calcium phosphate, treatment with a cation exchange resin to remove calcium and nucleotides, and finally, separation of PP1 from other phosphate compounds by chromatography on an anion exchange resin. The specific radioactivity of the PP1 eluted from the columns was determined and the concentration of PP1 in the original plasma could then be calculated.
The technique will be described in detail with the results of various tests applied to test the reproducibility and sensitivity of the method.
The measurement of PPI in human plasma 30-50 ml of venous blood was collected into glass vessels' surrounded by ice. These vessels contained heparin and sufficient known small amounts of 32P[PP1] (from the Radiochemical Centre, Amersham, England, initial specific activities 5-205 mCi/mmole) to allow a total initial activity of around 100,000 cpm. The 'P[PP,] was added in order to correct for subsequent losses of PP1. The collection of whole blood directly into the 3P [PP ,] appeared a valid procedure since the entire radioactivity remained outside the cells and could be completely recovered in the plasma after separation. Immediately after collection of the blood, ethylenediaminetetraacetate (EDTA) was added (1 ml of 200 mM EDTA disodium salt, adjusted to pH 7.4 with NaOH, was added for every 10 ml of blood). This addition of EDTA reduced the rate of hydrolysis of PP1 in the blood.
Thus preliminary studies had shown that, in plasma from patients with elevated alkaline phosphatase, the hydrolysis of PP1 by the end of ultrafiltration (see below) could reach 100%. This hydrolysis was reduced by the routine addition of EDTA to the blood. For example in three different blood samples kept at 00-40C (without EDTA) the hydrolysis of added 'P[PP1] ranged from 8 to 28% after 5 hr and from 28 to 67%o after 22 hr. The addition of EDTA reduced this hydrolysis to 5-10% during 22 hr.
An aliquot of blood was removed for determination of packed red cell volume and radioactivity (3 X 50 ul). The remainder of the blood was immediately centrifuged at 0°-4°C and the plasma separated. At this stage it is important that there should be no hemolysis, in order to avoid potential interference by red cell nucleotides. The blood should be centrifuged sufficiently hard to remove platelets and leucocytes. In practice, the centrifugation was either carried out in the presence of Plasaid beads (Stayne Laboratories Ltd., High Wycombe, Bucks, England) or the plasma was centrifuged twice.
If the analysis could not be performed immediately the plasma was frozen (at about -20'C) after separation.
After taking aliquots of plasma (3 X 50 1l) for determination of radioactivity, the plasma was equilibrated with a mixture of 5%o C02 and 95%o air and was then ultrafiltered at 20-60C. The equilibration with 5%o C02 before ultrafiltration was necessary in order to prevent the precipitation of calcium phosphate and coprecipitation of PP1. Ultrafiltration was carried out in a special apparatus constructed 'Glassware must not be washed in commercial detergents containing phosphates or polyphosphates.
of Perspex (Plexiglas). A yield of 11-26 ml of ultrafiltrate could be obtained from 15-30 ml of plasma ultrafiltered overnight through Visking dialysis membranes of about 6 cm diameter under a pressure of 5-S atmospheres (compressed air). Ultrafiltration proved superior to other methods of deproteinisation such as precipitation with alcohol or trichloroacetic acid.
The mean (±SEM) concentration of radioactivity in the ultrafiltrate from 43 plasma samples was 82 ±l% of the radioactivity in the original plasma. Some hydrolysis of the 'P[PPi] occurred during separation of the plasma and during ultrafiltration, even though all steps were carried out in the cold. This illustrates the importance of using an isotope dilution technique to correct for losses.
The PP1 was coprecipitated from the ultrafiltrate with calcium phosphate. This step is an important one since it allows the PP1 to be removed from many of the salts and other contaminating substances in the ultrafiltrate. It was based on the observation that calcium phosphates adsorb PPI very strongly (4, 9) . 0.5 N KOH was added until the ultrafiltrate was just yellow with methyl red as indicator, 250 mm CaCl2 was then added drop by drop until a copious precipitate had formed. The precipitate was recovered by centrifugation, dissolved in the cold in a minimum amount of 0.5 N HCl, and the volume made to 25 ml with water. A further 0.25 mmole of calcium was added, and the precipitation repeated by adding -0.5 N KOH. The precipitate was again dissolved in 0.5 N HC1 and diluted to 5 ml with water.
An excess (500 mg) of Dowex 50-W X 4 (200-400 mesh, sodium form, previously washed with 1 N NaOH, H20, 1 N HCl, H20, 1 M NaCl and H20) was then shaken with the dissolved precipitates for 2 min to remove calcium and nucleotides. Treatment with Dowex 50-W proved a better method of removing added adenosine di-and triphosphates (ADP and ATP) than acid-washed charcoal. The resin was removed by filtration through a glass sinter (G4) and washed four times with 3 ml of water. The filtrate and washings were collected in the cold in a vessel containing 0.5 ml of 0.2 M tris (hydroxymethyl) aminomethane base (Tris). The volume was made to 20 ml with H20 and the pH, measured with indicator paper, was checked to ensure that it was greater than 7.
The neutralized 20 ml of solution remaining after treatment with Dowex 50-W will be referred to later as "plasma extract." It was applied to columns containing anion exchange resin (Dowex 1 X 10, 100-200 mesh, chloride form). The resin was prepared by repeated alternate washings with 1 N NaOH, H20, 4 N HCl, and H20. Between runs the columns were regenerated with at least 100 ml of 4 N HCl, followed by washing with H20 until the effluent was chloride free. The columns were 17-20 cm long and had an internal diameter of 8.0-8.5 mm. Each column contained 10 ml of wet resin bed and had a flow rate of 0.5-1 ml/min. These columns are similar to those used for determination of PP1 in urine, as described previously (10, 11) . The columns were always of Pyrex glass, since some other types of glass, e.g. soda glass, adsorbed P1 and PP1 and this interfered with their separation. After washing the columns with 10 ml of water, P1 could be eluted either with 100 ml of 0.05 N HCl or with 200 ml of a solution of 0.133 M KC1 and 25 mm Na2B407 (in the latter case followed by 25 ml of H20 to remove salts if paper chromatography or repeat ion-exchange chromatography was to be carried out). For routine purposes we always use 0.05 N HCl to elute P1 because, although the KCl-borate solution gave better recoveries of PPi, the PP1 fractions sometimes contained traces of Pi due to adsorption of Pt to the columns. After elution of Pi, PP, was eluted with 0.25 N HCl, fractions being collected as 1 X 4 ml (fraction 1, 100-104 ml), 1 X 2 ml (fraction 2, 105-106 ml), 5 X 1 ml (fractions 3-7, 107-111 ml), and 3 X 2 ml (fractions 8-10, 112-117 ml). Aliquots (2 X 50 ,l) were taken from fractions 3-7 for determination of radioactivity. Concentrated HCl was then added to all the fractions to bring the HCl concentration in each to about 0.5 N HCL. The PP1 in the fractions was hydrolyzed to P by heating for 30 min in a boiling water bath. A volume of a reagent mixture (0.5%7o w/v ammonium molybdate and 2% w/v ascorbic acid dissolved in 1 N HCl) equal to that of the fraction was then added and the whole heated for 10 min in a boiling water bath. After cooling the P' was determined by measuring the extinction at 820 mA (molar extinction coefficient, E1 cm = 2.7 X 10') using semi-microcuvettes in a Beckman DU spectrophotometer. Whenever radioactivity due to 'P was measured, 50-,ul samples were applied in duplicate or triplicate to washed aluminum planchets sprayed with plastic film. When dry, the planchets were counted in an automatic methane gas flow counter (Frieseke and Hoepfner, Erlangen-Bruck, West Germany).
To calculate the concentration of PP in the original plasma, use was made of the principle of isotope dilution. The calculations are shown in the Appendix.
The value for specific activity of 'P[PP,] from ionexchange chromatography was taken as the mean activity of fractions 3-7 (107-111 ml) from the 0.25 N HCl eluates. The specific activities of these fractions were usually remarkably uniform, suggesting that only a single compound was eluted in these fractions (see Fig. 1 ). Occasionally, however, in our earlier studies, when the alkaline borate-KCl mixture was used to elute orthophosphate, there was an obvious progressive decrease in specific activity from fractions 5 through 7, presumably because these later fractions contained phosphate-reacting material that was not PP,. Detailed studies showed that this material was orthophosphate adsorbed to the columns. Interference from this source has now been eliminated by using 0.05 N HCl rather than the alkaline borate-KCl mixture to elute orthophosphate.
In order to determine whether other compounds are eluted with PP,, various other tests of specificity were carried out.
These included a second ion-exchange chromatography (Table I) , incubation with yeast pyrophosphatase, paper chromatography, and tests with added nucleotides. Repeat chromatography. When pooled fractions 3 and 4 from the 0.25 N HC1 elution from several columns were subjected to ion-exchange chromatography for a second time and the PP, was eluted with 0.09 N HCO in place of 0.25 N HCl, each fraction that contained '2P[PP,] had a specific activity not more than 10% higher than the P [PPp] in the pooled fractions (Table I) .
Incubation with pyrophosphatase. Yeast inorganic pyrophosphatase (12) was used to check the specificity of the method. This enzyme is highly specific for PP,, but under special conditions it will hydrolyze ATP (13 When hydrolysis of the 'P [PP,] in the plasma extract was practically complete, the solution was applied immediately to the ion-exchange columns, and the residual phosphate and radioactivity measured in fractions eluting with 0.25 N HCl between 100 and 117 ml (Fig. 1) .
After incubation of the plasma extract with pyrophosphatase before ion-exchange chromatography, the amount of phosphate-reacting material remaining in fractions 3-7 was equivalent to 0.24 ±0.05 (mean 'SE) m/Amoles PP,/ml of plasma. This represented 7 +1%o (mean ±SE) of the conccntration of PP1 in similar plasma extracts not treated with pyrophosphatase. An example of the effect of PP-ase is shown in Fig. 1 . It is clear that the major part of the 32P-labeled pyrophosphate and the phosphate-reacting material that eluted with 0.25 N HCl no longer does so after treatment with pyrophosphatase.
Ascending paper chromatography. Paper chromatography was carried out as follows. PP i-containing eluates from ion-exchange chromatography were collected under ice and were lyophilized at -5°C. The residue was dissolved in a minimum volume of water and applied to paper chromatograms (paper 2043b, Schleicher-Schill, Feldmeilen ZH, Switzerland). Internal standards of 82p[P,] and U'P[PP,]
were incorporated in some of the aliquots. Two solvent systems were used (the first contained 280 ml of isopropanol, 120 ml of H20, 16 g of trichloroacetic acid, and 1.2 ml of 20% NH40H; the second consisted of a 70: 30 (v/v) mixture of methanol and 2 N NH4OH). When the second solvent was used 200 ,ug of disodium EDTA was added to each spot. After. ascending chromatography had been carried out the 'P-containing spots were localized by radioautography. After this, chemically reacting phosphorus spots were localized by moistening the chromatogram with a mixture containing 1 g of ammonium molybdate, 3 ml of concentrated HCO, 3 ml of 70% perchloric acid, and 8 ml of water, all diluted to 100 ml with acetone. The chromatograms were then exposed to an UV lamp for 10 min and the resulting blue spots were stabilized by contact with NH3 vapor.
When fractions 3 and 4 from the 0.25 N HCl elution were pooled from several columns and treated in the way described above, the only detectable phosphorus-containing (blue) spot other than orthophosphate was superimposable upon the spot observed radioautographically and due to the tracer 'P [PP1] added to the blood. No spots were seen Effects of added nucleotides. One of the most serious potential sources of interference with the specificity of the method would be from adenine nucleotides. The concentration of such nucleotides is very low in plasma but is high in erythrocytes, and this is one reason why hemolyzed bloods were not taken for the analyses. Experiments were carried out in which ATP and ADP were added to whole blood to provide concentrations in blood of 10', 10-', and 10-' mole/liter (Table II) . Significant detectable interference only occurred at the highest concentration of each nucleotide (10-' mole/liter). At this concentration, separation of pyrophosphate and nucleotide on the column is only partial, so that the variable dilution of pyrophosphate by nucleotide causes variability in specific activity of the fractions, and it becomes impossible to calculate a value for pyrophosphate. At 10-' and 106 M nucleotide concentrations, this effect does not occur.
Recovery of PPI and reproducibility
Although the amount of 'P [PP] recovered in the 0.25 N HCl fractions from the columns was often as low as 20-30% of that present in the original blood, the concentration of PP1 in plasma could still be calculated since the specific activity of the PP1 could be measured accurately in the column eluates. When known amounts of nonradioactive PP1 were added to blood, the observed fall in the specific activity of the "'P[PP,] recovered from the columns was exactly as predicted (Table III) . This (15) .
Five of the cases of osteogenesis imperfecta were from a single family, in which a dominant mode of inheritance was present. Five of the remaining cases were the only known affected members in their families. Some of these cases were severely affected and three of the adults had had 40-70 fractures each.
The two cases of osteopetrosis were both mild, one hadbeen recognized when aged 7 yr and the other when aged 43 yr. The younger was on a low calcium diet plus cellulose phosphate for treatment.
None of the five cases of hyperparathyroidism had evidence of bone disease and the three cases of "acute" or "juvenile" osteoporosis (16) were studied after the phase of most rapid demineralization had occurred.
Normal persons were always bled at the same sessions as the patients, as an additional check on the technique for plasma PP,. Blood was usually taken in the morning, in the fasting state whenever possible. Urine pyrophosphate was measured by the technique of Fleisch and Bisaz (10) .
RESULTS
The concentration of PP1 in normal human plasma. The results are shown in Fig. 2 EDTA and "P[PPi] were added at the time of collection. This confirms that hydrolysis of PPi occurs during preparation of the plasma. Indeed similar studies on bloods containing large amount of alkaline phosphatase showed that plasma PPi concentrations approaching zero can be found, unless precautions are taken to cool the blood and to add EDTA at the beginning of the analysis.
When plasma PP1 was taken from seven normal persons several times during a single day, the variation found was greater than could be attributed to variation in the technique alone (Fig. 3) . These variations seemed unrelated to the time of day or time of meals so that other, as yet unidentified, factors may be playing a part. ---------------4-e Fig. 4 shows plasma PP1 values in eight patients with hypophosphatasia (17), 11 patients with osteogenesis imperfecta, 2 patients each with osteopetrosis or osteomalacia, 3 with "acute" osteoporosis of the juvenile type (16) , and 5 with primary hyperparathyroidism (without evidence of bone disease).
Plasma PP1 was invariably higher than normal in hypophosphatasia but was normal in osteogenesis imperfecta and osteopetrosis. Higher than normal values for plasma PP1 were found in two out of six relatives of patients with hypophosphatasia. All these six relatives were thought to be carriers (heterozygotes) of the disease (four mothers, one father, and one sister).
Plasma PPi was also above the upper limit of normal (plasma PPi = 8.35 and 7.6 Amoles/liter) in the two cases of osteomalacia due to intestinal malabsorption (one postgastrectomy and one due to gluten sensitivity).
Plasma PP1 was within the normal range in the other conditions studied.
DISCUSSION
The method finally adopted for the determination of PPi in plasma gave satisfactory results, considering the small quantities involved. This method, although laborious, makes it possible to study, for the first time, the factors that control the concentration of PPi in body fluids. It cannot be stated with certainty that no other compound is measured along with PPi, but the method appears better than 90% specific as judged by the elution patterns from the ion-exchange columns, by paper chromatography, and by incubation with inorganic pyrophosphatase. Interference from ATP and ADP at the concentrations likely to be encountered in blood was not detectable.
Apart from specificity, the other feature of major importance in the method is that 'P[PP1] is added at the moment the blood is collected. This allows corrections to be made for all losses, especially the considerable hydrolysis (up to 100% when the plasma alkaline phosphatase is raised) that occurs in absence of EDTA during the preparation of the plasma and ultrafiltrate. The only published report on measuring PP1 in human blood is that of Solomons and Styner (8) . These authors used serum for analysis and made no corrections for hydrolysis. The specificity of their technique was not adequately assessed, and the specific activity of 'P[PP1] in their various column fraction (Fig. 2, reference 8 (18) . Unfortunately, it is more difficult to obtain information of this sort in man. Thus it is not known whether PP1 in plasma is in equilibrium with the PPi in bone and whether the concentration of PPi in plasma is affected by local changes in the metabolism of PP1 in bone. In future studies these points will have to be clarified.
Hypophosphatasia was the only disease we studied in detail in which plasma PP1 was invariably above normal.
This observation is consistent with previous studies in which it was shown that urinary PP1 is always higher than normal in this condition (15, 19) . Because there is a deficiency of alkaline phosphatase in hypophosphatasia associated with high amounts of PP,, it is reasonable to assume that PP1 is one of the natural substrates for alkaline phosphatase in vivo. Indeed there is now excellent evidence that many mammalian alkaline phosphatases are able to hydrolyse PP1 (20) (21) (22) (23) (10, 11) . We measured urinary PP1 in five of our cases of osteogenesis imperfecta. None of them excreted more than 0.8 mg PPi per 100 mg of orthophosphate, which is the upper limit of normal in young persons (15) . At present, therefore, there is very little evidence to support the idea that an abnormality in PP1 metabolism may be the cause of osteogenesis imperfecta.
Plasma PP1 was normal in the other bone diseases we studied, with the exception of both the patients with osteomalacia. The significance of these changes will become evident only after further studies, but the findings in osteomalacia could suggest a role for vitamin D in removing PP1 so that calcification can proceed. Elevated plasma PPi concentrations have also been reported in some patients with renal failure (7), a condition in which abnormalities in the metabolism of vitamin D are also present (27) .
APPENDIX
The calculation of the concentration of PP1 in plasma, although straightforward is shown in detail so that the essential measurements and assumptions may be recognized.
(1) Total volume of blood from patient = VB ml. where Vp is the true volume of plasma present in the VB ml of blood taken from the patient. (9) If all the 32P[PPi] added initially to the blood remains outside cells and confined to plasma, then the total radioactivity (Rp) in (Vp + VEDTA) ml of plasma plus EDTA where RP = rP+EDTA' (VP + VEDTA) cpm, should be found to equal the total radioactivity at the beginning of the analysis, thus RP = RB+EDTA. Experimentally this was found to be so.
(10) Then, the total PP1 (,Ag) in Vp ml of plasma, defined as Tppi, = -P amount (,ug P) of 32P[PPi] added SAppi added initially.
(11) Thus concentration of PP1 in plasma = TPPi g P/ml. VP A
